

Michael Dougan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2043658/publications.pdf>

Version: 2024-02-01

89
papers

6,748
citations

136950
32
h-index

79698
73
g-index

90
all docs

90
docs citations

90
times ranked

12777
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine, 2020, 383, 2333-2344.	27.0	1,102
2	SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nature Communications, 2020, 11, 5493.	12.8	702
3	Immune Therapy for Cancer. Annual Review of Immunology, 2009, 27, 83-117.	21.8	545
4	De novo design of potent and selective mimics of IL-2 and IL-15. Nature, 2019, 565, 186-191.	27.8	362
5	GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. Immunity, 2019, 50, 796-811.	14.3	274
6	Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2646-54.	7.1	272
7	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell, 2020, 182, 655-671.e22.	28.9	259
8	Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7624-7631.	7.1	205
9	Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. Journal of Experimental Medicine, 2017, 214, 2243-2255.	8.5	187
10	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends in Immunology, 2019, 40, 511-523.	6.8	180
11	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology, 2020, 38, 576-583.	1.6	135
12	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Frontiers in Immunology, 2017, 8, 1547.	4.8	125
13	Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3912-3917.	7.1	121
14	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology, 2021, 160, 1384-1393.	1.3	121
15	IAP inhibitors enhance co-stimulation to promote tumor immunity. Journal of Experimental Medicine, 2010, 207, 2195-2206.	8.5	116
16	Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell, 2021, 184, 1575-1588.	28.9	111
17	Cancer Immunotherapy: Beyond Checkpoint Blockade. Annual Review of Cancer Biology, 2019, 3, 55-75.	4.5	102
18	Concurrent therapy with immune checkpoint inhibitors and TNF α blockade in patients with gastrointestinal immune-related adverse events. , 2019, 7, 226.		89

#	ARTICLE	IF	CITATIONS
19	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
20	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist, 2018, 23, 991-997.	3.7	86
21	Use of ¹⁸ F-2-Fluorodeoxyglucose to Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer. ACS Central Science, 2015, 1, 142-147.	11.3	85
22	A dual role for the immune response in a mouse model of inflammation-associated lung cancer. Journal of Clinical Investigation, 2011, 121, 2436-2446.	8.2	82
23	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. Cancer Immunology Research, 2018, 6, 389-401.	3.4	68
24	Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology, 2020, 76, 233-243.	2.9	66
25	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. Journal of Clinical Investigation, 2020, 130, 51-61.	8.2	66
26	Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. , 2019, 7, 292.		63
27	Immune receptor inhibition through enforced phosphatase recruitment. Nature, 2020, 586, 779-784.	27.8	59
28	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discovery, 2021, 11, 2564-2581.	9.4	58
29	Targeting Immunotherapy to the Tumor Microenvironment. Journal of Cellular Biochemistry, 2017, 118, 3049-3054.	2.6	54
30	Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments. Cancer Immunology Research, 2020, 8, 518-529.	3.4	54
31	Regulation of innate and adaptive antitumor immunity by IAP antagonists. Immunotherapy, 2018, 10, 787-796.	2.0	51
32	Liver biopsy findings in patients on immune checkpoint inhibitors. Modern Pathology, 2021, 34, 426-437.	5.5	48
33	A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. Clinical Infectious Diseases, 2022, 75, e440-e449.	5.8	46
34	Inciting inflammation: the RAGE about tumor promotion. Journal of Experimental Medicine, 2008, 205, 267-270.	8.5	45
35	Transnuclear TRP1-Specific CD8 T Cells with High or Low Affinity TCRs Show Equivalent Antitumor Activity. Cancer Immunology Research, 2013, 1, 99-111.	3.4	45
36	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. , 2020, 8, e000451.		39

#	ARTICLE	IF	CITATIONS
37	Immune checkpoint inhibitor-associated celiac disease. , 2020, 8, e000958.		38
38	Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer, 2020, 126, 3758-3767.	4.1	37
39	Antigen identification and high-throughput interaction mapping by reprogramming viral entry. Nature Methods, 2022, 19, 449-460.	19.0	32
40	Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist, 2020, 25, 6-14.	3.7	31
41	Programmable bacteria as cancer therapy. Nature Medicine, 2019, 25, 1030-1031.	30.7	29
42	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6129-6143.	2.2	28
43	IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells. Cancer Immunology Research, 2018, 6, 25-35.	3.4	27
44	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Medicine, 2019, 8, 4986-4999.	2.8	27
45	Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. Molecular Cancer Therapeutics, 2017, 16, 428-439.	4.1	25
46	clAP1/2 antagonism eliminates MHC class II-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Science Translational Medicine, 2021, 13, .	12.4	25
47	Cancer immunotherapy-related adverse events: causes and challenges. Supportive Care in Cancer, 2020, 28, 6111-6117.	2.2	22
48	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6119-6128.	2.2	20
49	Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. Current Gastroenterology Reports, 2020, 22, 15.	2.5	20
50	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		20
51	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist, 2021, 26, 514-522.	3.7	18
52	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Supportive Care in Cancer, 2020, 28, 6175-6181.	2.2	15
53	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer, 2020, 28, 6145-6157.	2.2	14
54	Type 2 immunity is maintained during cancer-associated adipose tissue wasting. Immunotherapy Advances, 2021, 1, ltab011.	3.0	13

#	ARTICLE	IF	CITATIONS
55	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6159-6173.	2.2	11
56	Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. , 2020, 8, e001329.		11
57	Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biology, 2020, 10, 190235.	3.6	11
58	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. Seminars in Immunology, 2021, 52, 101473.	5.6	11
59	Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. , 2019, 7, 41.		10
60	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	3.7	10
61	Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. Cancer Immunology Research, 2020, 8, 1230-1235.	3.4	10
62	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunotherapy Advances, 2021, 1, ltab014.	3.0	10
63	Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?. Journal of Clinical Oncology, 2018, 36, 127-127.	1.6	10
64	Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 743-746.	1.2	9
65	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
66	Tissue eosinophils express the IL-33 receptor ST2 and type 2 cytokines in patients with eosinophilic esophagitis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 656-660.	5.7	8
67	Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy. Frontiers in Immunology, 2022, 13, 871452.	4.8	8
68	Elevated circulating memory T cells precede immunotherapy toxicities in melanoma. Trends in Cancer, 2022, , .	7.4	7
69	Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process. Open Forum Infectious Diseases, 2021, 8, ofab546.	0.9	6
70	The Association Between Symptoms and COVID-19 Test Results Among Healthcare Workers. Annals of Surgery, 2020, 272, e329-e332.	4.2	5
71	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.. Journal of Clinical Oncology, 2018, 36, 3096-3096.	1.6	4
72	Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis.. Journal of Clinical Oncology, 2020, 38, 89-89.	1.6	4

#	ARTICLE	IF	CITATIONS
73	The Landscape of COVID-19 Research in the United States: a Cross-sectional Study of Randomized Trials Registered on ClinicalTrials.Gov. Journal of General Internal Medicine, 2022, 37, 154-161.	2.6	4
74	Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th,) Tj ETQq0 0 0rgBT /Over	4.4	3
75	Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed. Gastroenterology, 2021, 161, 1106-1108.	1.3	3
76	Multi-detector computed tomography (MDCT)–based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. European Radiology, 2021, 31, 8868-8878.	4.5	2
77	Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2018, 36, 3087-3087.	1.6	2
78	Engineering T cell memory for antitumor immunity. Trends in Pharmacological Sciences, 2022, 43, 1-3.	8.7	2
79	Performance of a Triage Protocol for Monoclonal Antibodies in a Mixed Vaccinated and Unvaccinated Cohort of Covid-19 Patients Treated with Intravenous Infusion or Subcutaneous Injection. Open Forum Infectious Diseases, 0, , .	0.9	2
80	SMAC mimetics throw a molecular switch to control T _H 17 responses. Science Signaling, 2019, 12, .	3.6	1
81	Reply to Y. Inagaki et al. Journal of Clinical Oncology, 2020, 38, 1749-1750.	1.6	1
82	Flu vaccination rate of patients with severe immune-related adverse events.. Journal of Clinical Oncology, 2019, 37, e18234-e18234.	1.6	1
83	Progressive chronic kidney function decline as a clinical presentation of immune checkpoint inhibitor-associated nephrotoxicity. Journal of Onco-Nephrology, 0, , 239936932210877.	0.6	1
84	Editorial: Penetration of food protein through the oesophageal mucosa–is this where EoE starts?. Alimentary Pharmacology and Therapeutics, 2021, 53, 447-448.	3.7	1
85	Immune-related adverse events: what we’ve learned and where we’re heading. Expert Review of Anticancer Therapy, 2020, 20, 727-730.	2.4	0
86	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 2654-2654.	1.6	0
87	Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T Cell Effector Function in Mice: Implications for Combination with Immunotherapy. Blood, 2016, 128, 2525-2525.	1.4	0
88	Factors associated with severity of immune checkpoint inhibitor gastroenterocolitis requiring hospitalization in melanoma patients.. Journal of Clinical Oncology, 2019, 37, 81-81.	1.6	0
89	Case 14-2022: A 57-Year-Old Man with Chylous Ascites. New England Journal of Medicine, 2022, 386, 1834-1844.	27.0	0